Lue, J. K., Stevens, D. A., Williams, M. E., Westin, J., Ewesuedo, R., McDonald, A., Agarwal, S., Henrick, P., Perea, R., & Gollob, J. (2022). Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 140(Supplement 1), 12143–12144. https://doi.org/10.1182/blood-2022-170151